Medical Affairs

Medical Affairs departments vary enormously in size, structure, scope and sophistication. Understanding this variation is essential for anyone looking to build, optimise or benchmark a Medical Affairs function.

At one end of the spectrum are small biotechs with a single Medical Director juggling every medical responsibility from clinical trial design to KOL engagement. At the other end are global pharmaceutical giants with hundreds of Medical Affairs professionals organised into specialised sub-functions spanning medical information, evidence generation, external engagement and medical operations.

Between these extremes lies a vast range of configurations, each shaped by factors such as:

• Company size and stage: Early-stage biotechs need flexible, generalist Medical Affairs capabilities. Large pharma can afford deep specialisation.
• Therapeutic area complexity: Oncology and rare diseases typically demand more sophisticated Medical Affairs capabilities than primary care indications.
• Geographic scope: Global organisations require robust infrastructure for cross-border collaboration and local market adaptation.
• Product lifecycle: Pre-launch, launch and mature products each require different Medical Affairs priorities and skills.
• Regulatory environment: Markets with complex HTA and reimbursement processes need stronger evidence generation and payer engagement capabilities.

This variation means there is no single 'right' way to structure a Medical Affairs department. The optimal design depends on the specific context, challenges and strategic priorities of the organisation.

At LUCENT, we help companies navigate this complexity, designing Medical Affairs functions that are tailored to their unique needs and positioned to deliver maximum strategic impact.